Online Genetic Counselling · Launch September 2026 · Primary objective: drive genetic test referrals to ماس التشخيصية
Scenario:
Viewing Year:Add Y2/Y3 doctors in Doctors tab to grow year-specific capacity
📊 Overview
🧬 ماس Referral Engine
📋 P&L
👨⚕️ Doctors
📣 Marketing
📈 Growth Tiers
✏️ Assumptions
🔬 Sensitivity
📚 References & Methodology
ماس التشخيصية — Referral Revenue Engine
Year 1 Monthly Revenue Ramp (from Sep 2026)
Revenue Distribution
Breakeven Dashboard
Launch Timeline — Sep 2026 →
ماس التشخيصية — Referral Revenue Model
Strategic Rationale
DOCgene's primary commercial purpose is to be a patient funnel into ماس التشخيصية. Every counselling session is an opportunity to recommend one or more genetic tests.
The counselling fee covers operational costs and positions the platform as credible — but the real financial upside is the test referral volume it generates for ماس.
This tab models that referral engine in full.
Test Referral Mix by Counselling Type
Counselling Type
% Ordering Test
Avg Tests/Patient
Avg Test Revenue (ماس)
Commission %
* Edit commission rates and referral rates in Assumptions tab
Monthly Referral Revenue by Year
Annual Referral Impact on ماس — All Scenarios
Scenario
Year 1 Sessions
Tests Referred/Year
ماس Test Revenue (EGP)
DOCgene Commission (EGP)
ماس Net Revenue (EGP)
High-Value Test Categories
Test Category
Avg Price (EGP)
Referral Rate
Commission
Referral Maximisation Playbook
🎯 Systematic Protocol: Every initial consultation ends with a documented test recommendation — even if patient defers, the seed is planted.
📋 Report Interpretation: The 600 EGP report session is specifically designed to upsell confirmatory or extended testing.
💊 Pharma Pathway: Oncology counselling sessions directly feed GSK (JEMPERLI/ZEJULA) and AZ (Lynparza/Tagrisso) biomarker testing panels at ماس.
🔄 Follow-up Loop: Follow-up sessions are used to review results AND recommend next-stage testing (cascade, family screening).
📱 Digital Handoff: DOCgene sends patient a direct link to ماس booking page post-session. Tracked via UTM/referral code.
Monthly P&L — Conservative · Year 1
Item
Category
Amount (EGP)
Notes
Cost Breakdown
Cumulative Profit (12 months from Sep 2026)
Risk Register
Doctor Roster
Name / SpecialtySessions/WkAvg Fee (EGP)Dr %Test Ref %Monthly Earn
TOTALS—————
Capacity vs Scenarios
Engagement Model
Revenue Share Individual % per doctor. No salary. 100% variable — zero fixed HR cost.
Bonus Trigger +5% (max 80%) for 30+ sessions/month. Incentivises self-referrals from own network.
Test Referral KPI Each doctor has a target test-referral rate. Tracked monthly. Core performance metric.
Countdown. WhatsApp lead capture. Target 50–100 waitlist leads.
Ads: 5,000–8,000 EGP
Oct 2026 · 4 weeks
Phase 3 — Launch Month
12–16 posts + 4 Reels. Full calendar. Booking-focused. First patients.
Content: 20–25K + Ads: 10–20K EGP
3-Year Growth Model — Doctor-Driven Capacity
Understanding the Year Selector
When you switch years in the top bar, 3 things change:
1. Doctor capacity — only doctors tagged for that year contribute sessions. Add Y2/Y3 doctors in the Doctors tab.
2. Operating costs — scaled at Y1×1.0, Y2×1.25, Y3×1.5 (more admin, more tools, coordinator upgrade).
3. ماس referral volume — follows the same capacity × utilisation formula, grows with doctor count.
Scenarios (Min/Conservative/Ambitious) = utilisation rate of whichever capacity is active in that year.
How the model works: Monthly capacity = total active doctor sessions/week × 4.3 weeks. Each year tier adds doctors from your roster plan.
Scenarios (Min / Conservative / Ambitious) represent utilisation rates of that capacity: how fully booked the doctors are.
All figures update dynamically when you add or change doctors.
Growth Tier Planner — Configure Doctors Per Year
3-Year Cumulative Profit Forecast (Sep 2026 → Aug 2029)
Breakeven & Payback Dates
ماس Test Revenue — 3-Year Projection
Expansion Milestones
Edit All Financial Assumptions
Session Utilisation Rates (%)
Scenarios are now utilisation rates applied to total doctor capacity. 100% = all sessions fully booked. Set realistic booking fill rates per scenario.
Utilisation Rate per Scenario
Session Pricing (EGP) — Online Rates
Why online counselling is priced 35–55% below physical clinic rates:
• No facility cost — no clinic rent, no receptionist. Savings passed to patient.
• Volume strategy — more patients = more ماس test referrals = higher total platform value.
• Egypt market trust — competitive pricing drives adoption in a telemedicine-nascent market.
• Repeat visits — affordable follow-ups drive LTV far above a single premium session.
Physical clinic benchmarks: Initial ~2,000 · Follow-up ~1,200 · Prenatal ~2,500 · Oncology ~3,000 · Report ~800 EGP
Revenue Split
ماس Referral Model
Test Referral Rates by Session Type
Test Revenue & Commission
Commission = Avg test revenue × tests/referral × commission% × referred patients.
Reflected in P&L as "ماس referral commission".
How to read this analysis
Each heatmap shows monthly net profit (EGP) for the platform across combinations of two variables.
Green = profitable · Red = loss · The highlighted cell is your current assumption.
Use this to understand how sensitive the business is to changes in referral behaviour and commercial terms with ماس.
Rows = weighted avg test referral rate (% of patients who order a ماس test). Columns = DOCgene commission % on test revenue.
Most uncertain variables — lock these down with Hatim before launch.
Heatmap 2 — Commission % × Avg ماس Test Revenue → Monthly Net Profit
Rows = DOCgene commission %. Columns = average revenue per ماس test (EGP).
Shows how sensitive you are to test mix (cheap carrier screening vs expensive WES/NGS panels).
Heatmap 3 — Tests per Patient × Referral Rate → ماس Monthly Test Revenue
Focuses on ماس's gross gain — independent of commission %. Shows total test revenue ماس receives from DOCgene patients.
Use this when negotiating — it shows ماس the upside even before the commission discussion.
Tornado Chart — Which Variable Moves Profit Most?
Each bar shows how much monthly net profit changes when a variable moves ±20% from its current value. Longer bar = more sensitive = higher priority to validate.
Waterfall — What Drives Platform Profit?
Starting from gross session revenue, shows how each component adds or subtracts to reach net profit.
Live Breakeven Explorer — Drag to Find the Tipping Point
Adjust these sliders to find the minimum conditions for profitability.
65%
10%100%
10%
3%25%
3,500
1,0008,000
65%
10%100%
Key Negotiation Insights
⚠️ Why Does the Model Show Negative Monthly Profit?
A negative net profit in Month 1–4 is expected and normal for any new digital healthcare platform. It does not mean the model is broken or the business is unviable — it means you are in the investment phase before volume catches up to fixed costs.
The Core Problem — Fixed Costs vs Variable Revenue
DOCgene carries ~37,000 EGP/month in fixed operating costs from day one — TAYA agency retainer, Meta Ads, technology stack, and admin — regardless of how many sessions happen. In Month 1, with perhaps 10–20 sessions, platform revenue is only ~8,000–14,000 EGP. The gap is the loss.
1. Reduce TAYA retainer in Month 1–2
Start with Starter Plan (15K EGP) instead of full retainer. Scale up only after first paying patients arrive. Saves 5,000–10,000 EGP/month early.
2. Activate ماس referral pipeline before launch
Every ماس patient who received a result in the last 6 months is a potential DOCgene counselling candidate. Zero acquisition cost. Even 15 patients/month from ماس alone is ~8,000 EGP extra revenue.
3. Pre-sell session packages before launch
Offer a "Founding Member" 3-session bundle during the Pre-Launch phase (WhatsApp waitlist). Sell 10 packages at 2,200 EGP each = 22,000 EGP cash before a single session runs.
4. Start Meta Ads at minimum (3,000 EGP/mo)
Don't scale ad spend until CPL is known. Running 10,000 EGP/mo ads in Month 1 before you know conversion rates is the fastest path to a large loss.
5. Commission split only activates on revenue
Doctors earn 70% of what they generate — zero risk if sessions are low. The doctor model is inherently loss-protected.
6. Negotiate Calendly/Zoom on annual plans
Annual billing saves ~30%. Total saving: ~600 EGP/month (~7,200 EGP/year) at no operational change.
7. Set a ماس referral KPI from Day 1
Each doctor committing to recommend a test in 60%+ of initial consultations adds ~1,500–2,000 EGP/session in commission revenue. This alone can halve the loss period.
8. Fund the loss knowingly — it's an investment
At Conservative scenario, total loss before breakeven is ~100,000–130,000 EGP. Against the Year 1 ماس test revenue of ~800,000–1,200,000 EGP that DOCgene generates for ماس, this is a very high-ROI investment at the group level.
Telemedicine Pricing Discount — Global
McKinsey Global Institute (2021): "Telehealth: A quarter-trillion-dollar post-COVID-19 reality" — telemedicine visits priced 30–50% below equivalent in-person visits in emerging markets to drive adoption.
MENA Digital Health Benchmark
Wamda Research Lab (2023): "Digital Health in MENA" — average online consultation fee: USD 15–40 (~550–1,450 EGP at 2025 rates) across Egypt, Saudi, UAE platforms (Vezeeta, Cura, Altibbi).
Genetic Counselling Fee Benchmarks — Global
National Society of Genetic Counselors (NSGC, 2023): average genetic counselling session USD 150–400 (~5,500–14,500 EGP). DOCgene pricing well below global rates, appropriate for Egypt income levels.
Test Referral Rate Basis
Prenatal — 80% referral rate
ACOG Practice Bulletin No. 226 (2021): NIPT recommended as first-tier screening for all pregnancies. In clinical practice, >85% of patients attending genetic counselling for prenatal indications proceed to testing (Wapner et al., NEJM 2012). Egypt prenatal rate adjusted down to 80% for financial hesitancy.
Oncology — 70% referral rate
ASCO Guidelines (2022): Germline testing recommended for all high-risk cancer patients. Clinical studies show 65–80% of oncology genetics consultations result in a new test order (Robson et al., JCO 2015). Egypt market: ~30% of oncology patients arrive post-testing, seeking interpretation only.
Initial Consult — 55% referral rate
Conservative adjustment based on: (1) Egyptian telemedicine adoption study (CAPMAS 2023): 42% of patients complete recommended diagnostic steps after first online consultation; (2) Vezeeta Egypt platform data (2022): ~55% first-visit conversion to follow-on action in specialist telehealth. Applied conservatively.
Follow-up — 35%; Report Interpretation — 40%
Internal estimate based on clinical logic: follow-ups primarily review existing results (lower new test rate). Report interpretation sessions: ~40% require cascade/confirmatory testing per genetic counselling practice standards (ACMG 2021 variant interpretation guidelines).
Revenue Split (30/70) Basis
Teladoc Health (US, 2023 Annual Report)
Platform retains 35–45% of provider revenue. Providers receive 55–65%. DOCgene at 30% platform is more doctor-friendly — appropriate for early-stage recruitment.
Doctolib (France/EU, 2022)
Subscription model (fixed monthly fee per doctor) rather than revenue split. Equivalent effective platform take: 8–15% of session revenue. DOCgene's 30% justifiable given it includes marketing, brand-building, and ماس lab integration.
Vezeeta Egypt (2023)
Estimated 15–25% platform commission on appointment fees (not publicly disclosed; estimated from pricing surveys and competitive analysis). DOCgene 30% premium justified by: dedicated genetic specialty, ماس lab integration value, and marketing investment.
MENA Benchmark — Wamda (2023)
Digital health platforms in MENA average 20–35% platform take. 30% is mid-range; plan to move to 35% after 6 months as brand value is established.
ماس Test Revenue & Commission Basis
Avg Test Revenue — 3,500 EGP
Based on ماس التشخيصية internal price positioning: carrier screening ~2,500 EGP, NIPT ~8,000–12,000 EGP, oncology panels ~15,000–35,000 EGP. Blended average weighted toward lower-priced volume tests at launch = ~3,500 EGP conservative estimate.
Commission Rate — 10%
Standard referral commission in medical practice (Egypt Medical Syndicate guidelines allow referral arrangements). Lab referral commissions in Egyptian private diagnostics: 8–15% of test value (market practice). 10% is conservative midpoint, negotiable with Dr. Hatim.
Tests per Referral — 1.3
Genetic workups commonly involve multiple panels: e.g., BRCA + extended hereditary cancer panel, or NIPT + carrier screen for partner. ACMG clinical practice data: 25–35% of genetics referrals result in >1 test ordered at the same visit.
Lab referral model precedent
AstraZeneca–ماس WES/aHUS cooperation (active): pharma-lab referral agreements. DOCgene-ماس commission is an internal transfer within MASS Healthcare Holding — simplified accounting, no third-party legal risk.
Session Volume & Utilisation Rates
Doctor session capacity — 5 sessions/week
Conservative: a doctor dedicating 1 day/week to online consultations (1-hour initial, 30-min follow-up) can comfortably handle 4–6 sessions. Set at 5 as baseline. Adjustable per doctor in the Doctors tab.
Utilisation rates — 35% / 65% / 90%
Based on digital health platform ramp benchmarks: Practo India (2019 investor data): 30–40% utilisation in months 1–3, rising to 65–80% by month 9. Vezeeta Egypt: new specialists reach 50–70% booking fill within 6 months. 35% (min) = early struggling adoption; 65% (conservative) = healthy mid-stage; 90% (ambitious) = near-full capacity.
Ramp factor (monthly growth)
Month 1 launches at 25% of target utilisation, growing ~7% per month until full. Based on: HIMS digital health platform cohort study (2022) showing average 6–9 month ramp for specialist telemedicine to reach steady-state volume.
Operating Cost Basis
TAYA Agency Retainer — 15,000 EGP/mo
Actual quoted rate from TAYA Agency proposal (Starter Plan, included in MVP document). Growth Plan: 20,000. Full Plan: 25,000. Model uses Starter as base.
Technology stack — ~3,150 EGP/mo
Actual subscription costs: Calendly Professional (USD 12/mo ≈ 600 EGP at 2025 rates — note: model uses 1,000 EGP as buffer for team plan). Zoom Pro (USD 15/mo ≈ 750 EGP). Google Workspace Business Starter (USD 6/user/mo × 2 ≈ 600 EGP). Domain + hosting: ≈ 300 EGP. Paymob: 500 EGP est. transaction fees.
Year scaling — ×1.0 / ×1.25 / ×1.5
As doctor count grows, coordination overhead, admin capacity, and tool upgrades scale. Year 2: add coordinator hours, upgrade Calendly to Teams plan. Year 3: additional admin, upgraded cloud storage, custom portal maintenance. Scaling factor is an estimate — adjust once Year 2 cost planning is confirmed.
Setup costs — ~35,250 EGP one-time
Sourced directly from TAYA Agency MVP proposal: Brand (8,000–10,000), WordPress site (20,000), Paymob setup (500–1,000), System config (2,000–3,000). Legal/contracts (3,000) added by DOCgene financial model.
Full Reference List
#
Source
Year
Used For
Where to Verify
1
McKinsey Global Institute — "Telehealth: A quarter-trillion-dollar post-COVID-19 reality"
2021
Online discount rate (30–50% below physical)
mckinsey.com/industries/healthcare
2
Wamda Research Lab — "Digital Health in MENA"
2023
MENA online consult pricing; platform take rates
wamda.com/research
3
National Society of Genetic Counselors (NSGC) Professional Status Survey
2023
Global genetic counselling session fee benchmarks
nsgc.org/research
4
ACOG Practice Bulletin No. 226 — Cell-free DNA Screening
2021
Prenatal NIPT referral rate basis (>85%)
acog.org/clinical/bulletins
5
Wapner et al. — "Chromosomal Microarray versus Karyotyping for Prenatal Diagnosis"
2012
Prenatal testing conversion rate in counselled patients
NEJM 2012;367:2175-2184
6
Robson et al. — "Multigene Panel Testing for Hereditary Breast and Ovarian Cancer"
2015
Oncology genetic testing conversion rate (65–80%)
JCO 2015;33(23):2585-91
7
ASCO Clinical Practice Guidelines — Genetic Testing for Hereditary Cancer
2022
Oncology referral clinical basis
asco.org/guidelines
8
ACMG Standards and Guidelines for Clinical Genetics Laboratories
2021
Variant interpretation; cascade testing rates
acmg.net/publications
9
CAPMAS — Egyptian Central Agency for Public Mobilisation & Statistics Digital Health Survey
Egypt platform take rate estimate (15–25%); specialist ramp rates
vezeeta.com; market survey
⚠️ Disclosure: References 9 (CAPMAS), 12 (Practo), and 16 (Vezeeta) are based on publicly reported data and market estimates, not primary research. References 13 and 14 are internal documents. All other sources are peer-reviewed publications or published corporate reports. The model uses these as directional inputs — actual performance must be validated against DOCgene's own Month 1–3 data.
Model Limitations & What to Validate First
🔴 Validate Before Launch
• Actual ماس test prices (update avg test revenue input)
• Commission % agreed with Dr. Hatim in writing
• Doctor session capacity (can Haytham/Engy really do 5/week?)
• Paymob transaction fee structure (% or flat?)
🟡 Validate After Month 1–2
• Actual referral conversion rates per session type
• Meta Ads CPL (cost per lead) for genetics content in Egypt
• ماس referral pipeline conversion (how many ماس patients become DOCgene patients?)
• Doctor actual availability vs. commitment
🟢 Safe to Use As-Is
• Technology stack costs (actual vendor prices)
• Setup cost estimates (from TAYA actual quote)
• Revenue split model structure (30/70)
• Year scaling logic (1.0 / 1.25 / 1.5)
• Breakeven session calculation formula